Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is experiencing consistent organic growth and has exceeded expectations in both US sales and international sales, indicating strong market demand. The company is also evolving its product to provide integration with insulin pumps, which could drive further growth and establish a strong competitive moat. Despite facing potential risks such as regulatory hurdles and competition, DexCom has demonstrated strong margins and consistent FCF performance, making it a favorable investment opportunity in the diabetes device industry.

Bears say

DexCom is facing multiple challenges, including regulatory delays impacting future revenues and a potentially smaller market opportunity than projected, potentially limiting their revenue growth potential. These challenges, combined with some slight multiple compression since the last valuation update, warrant a negative outlook on the stock. Additionally, while management has reiterated all previously provided guidance metrics, there is uncertainty surrounding regulatory requirements at the FDA, which could impact the company's ability to meet its projected revenue and earnings growth goals. Overall, there is likely limited upside potential for DexCom in the near future, leading to a negative outlook on the stock.

DexCom (DXCM) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 22 analysts, DexCom (DXCM) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.